These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10778683)

  • 1. Clinical relevance of reduced bioavailability of rifampicin.
    Joshi SR
    J Assoc Physicians India; 1999 Sep; 47(9):943-4. PubMed ID: 10778683
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of reduced bioavailability of rifampicin.
    Bhatt AD; Vaz JA; Padgaonkar KA
    J Assoc Physicians India; 1998 Aug; 46(8):729-31. PubMed ID: 11229285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
    Avachat AM; Bhise SB
    Pharm Dev Technol; 2011 Apr; 16(2):127-36. PubMed ID: 20105081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
    Dixit R; Sharma S; Nawal CL
    J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
    [No Abstract]   [Full Text] [Related]  

  • 8. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
    McIlleron H; Wash P; Burger A; Folb P; Smith P
    Int J Tuberc Lung Dis; 2002 Apr; 6(4):356-61. PubMed ID: 11936746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse effects related to the use of antitubercular drugs in psychiatric centers: retrospective study at the Philippe Pinel CH in Amiens 1994].
    Decocq G; Compagnon M; Andréjak M; Guedj B; Doutrellot C
    Therapie; 1996; 51(5):543-9. PubMed ID: 9138390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinico-laboratory diagnosis of adverse reactions in children to antitubercular drugs in different combinations].
    Kazakov KS; Zakharova RI; Absadykova FT
    Probl Tuberk; 1990; (9):40-2. PubMed ID: 2274509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alopecia areata in a patient treated with antitubercular drugs].
    Tella E; Daubercies G; Sin C; Marchal A; Sigal ML; Mahé E
    Ann Dermatol Venereol; 2014 Apr; 141(4):295-7. PubMed ID: 24703645
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
    Singh S; Mohan B
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation.
    Shishoo CJ; Shah SA; Rathod IS; Savale SS; Vora MJ
    Int J Pharm; 2001 Oct; 228(1-2):53-67. PubMed ID: 11576768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reaction to antimycobacterials administered as a combination tablet with no reaction to the same drugs in isolation.
    Kingston M; Childs K; Carlin E
    Sex Transm Infect; 2001 Oct; 77(5):392-3. PubMed ID: 11588298
    [No Abstract]   [Full Text] [Related]  

  • 18. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Assefa Y; Assefa Y; Woldeyohannes S; Hamada Y; Getahun H
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    van Ingen J; Aarnoutse RE; Donald PR; Diacon AH; Dawson R; Plemper van Balen G; Gillespie SH; Boeree MJ
    Clin Infect Dis; 2011 May; 52(9):e194-9. PubMed ID: 21467012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
    Bhaduri J
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1128-9; author reply 1129. PubMed ID: 12546124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.